Skip to main content
SpringerLink
Log in

Benefits and risks of third-generation oral contraceptives

  • Clinical Reviews
  • Published:
Journal of General Internal Medicine Aims and scope Submit manuscript

Abstract

OBJECTIVE: To evaluate the risks and benefits of third-generation oral contraceptives.

DATA SOURCES: A medline search was done for English language articles published from 1985 through 1998 relating to the side-effect profile of third-generation oral contraceptives or their association with cardiovascular or thromboembolic disease. All articles containing original data were included.

DATA SYNTHESIS: The risk of venous thromboembolism appears to be 1.5- to 2.7-fold greater in users of third-generation, compared with second-generation, oral contraceptives. Compared with nonusers, women who use third-generation oral contraceptives may have a 4.8- to 9.4-fold greater risk of venous thromboembolism. Users of third-generation oral contraceptives do not appear to have an increased risk of myocardial infarction compared with nonusers and may have risk of myocardial infarction of 0.26 to 0.7 compared with second-generation users. Whether third-generation oral contraceptives are associated with a decreased stroke risk is still not clear.

CONCLUSIONS: Although third-generation oral contraceptives most likely increase a user’s risk of venous thromboembolism, their improved side-effect profile and their possible decreased association with myocardial infarction and stroke may make them a useful new class of oral contraceptives for most women except those at increased risk of venous thrombosis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Stampfer MJ, Willet WC, Colditz GA, Speizer FE, Hennekens CH. A prospective study of past use of oral contraceptive agents and risk of cardiovascular diseases. N Engl J Med. 1988;319:1313–7.

    Article  PubMed  CAS  Google Scholar 

  2. Lewis M, Heinemann A, Spitzer W, MacRae K, Bruppacher R, for the Transnational Research Group on Oral Contraceptives and the Health of Young Women. The use of oral contraceptives and the occurrence of acute myocardial infarction in young women. Contraception. 1997;56:129–40.

    Article  PubMed  CAS  Google Scholar 

  3. Petiti D, Sidney S, Bernstein A, Wolf S, Quesenberry C, Ziel H. Stroke in users of low-dose oral contraceptives. N Engl J Med. 1996;335:8–15.

    Article  Google Scholar 

  4. Schwartz S, Siscovick D, Longstreth WT Jr, Psay B, Beverly K. Use of low-dose oral contraceptives and stoke in young women. Ann Intern Med. 1997;127:596–603.

    PubMed  CAS  Google Scholar 

  5. Runnebaum B, Grunwald K, Rabe T. The efficacy and tolerability of norgestimate/ethinyl estradiol (250 µg of norgestimate/35 µg of ethinyl estradiol): results of an open, multicenter study of 59,701 women. Am J Obstet. 1992;166:1963–8.

    CAS  Google Scholar 

  6. Palatsi R, Hirvensalo E, Liukko P, et al. Serum total and unbound testosterone and sex hormone binding globulin (SHBG) in female acne patients treated with two different oral contraceptives. Acta Derm Venereol (Stockh). 1984;64:517–23.

    CAS  Google Scholar 

  7. Bilotta P, Favilli S. Clinical evaluation of a monophasic ethinyl estradiol/desogestrel-containing oral contraceptive. Arzneim-Forsch Drug Res. 1988;36:932–4.

    Google Scholar 

  8. Corson SL. Efficacy and clinical profile of a new oral contraceptive containing norgestimate. Acta Obstet Gynecol Scand. 1990;152(suppl):25–31.

    CAS  Google Scholar 

  9. Huber J. Clinical experience with a new norgestimate-containing oral contraceptive. Int J Fertil. 1991;36(suppl):25–31.

    PubMed  Google Scholar 

  10. Chapdelaine A, Desmarais J, Derman RJ. Clinical evidence of the minimal androgenic activity of norgestimate. Int J Fertil. 1989;34:347–52.

    PubMed  CAS  Google Scholar 

  11. Cullberg G, Samsioe G, Andersen RF, et al. Two oral contraceptives, efficacy, serum proteins, and lipid metabolism: a comparative multicentre study on a triphasic and a fixed dose combination. Contraception. 1982;26:229–43.

    Article  PubMed  CAS  Google Scholar 

  12. Walling M. A multicenter efficacy and safety study of an oral contraceptive containing 150 µg desogestrel and 30 µg ethinyl estradiol. Contraception. 1992;46:313–26.

    Article  PubMed  CAS  Google Scholar 

  13. Andolsek KM. Cycle control with triphasic norgestimate and ethinyl estradiol, a new oral contraceptive agent. Acta Obstet Gynecol Scand. 1992;71:22–6.

    Google Scholar 

  14. Hoppe G. Gestodene, an innovative progestogen. Contraception. 1988;37:493–501.

    Article  PubMed  CAS  Google Scholar 

  15. Speroff L, DeCherney A, and The Advisory Board for the New Progestins. Evaluation of a new generation of oral contraceptives. Obstet Gynecol. 1993;81:1034–47.

    PubMed  CAS  Google Scholar 

  16. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Venous thromboembolic disease and oral contraceptives: results of international multicentre case-control study. Lancet. 1995;346:1575–82.

    Article  Google Scholar 

  17. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease. Lancet. 1995;346:1582–88.

    Article  Google Scholar 

  18. Spitzer WO, Lewis AL, Heinemann LAJ, Thorogood M, MacRae KD, on behalf of the Transnational Research Group on Oral Contraceptives and the Health of Young Women. Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study. BMJ. 1996;312:83–8.

    PubMed  CAS  Google Scholar 

  19. Bloemenkamp K, Rosendaal FR, Helmerhorst FM, Buller H, Vandenbroucke J. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen. Lancet. 1995;346:1593–6.

    Article  PubMed  CAS  Google Scholar 

  20. Lidegaard O, Edstrom B, Kreiner S. Oral contraceptives and venous thromboembolism: a case control study. Contraception. 1998;57:291–301.

    Article  PubMed  CAS  Google Scholar 

  21. Bloemenkamp K, Rosendaal F, Buller H, Helmerhorst F, Colly LP, Vandenbroucke J. Risk of venous thrombosis with use of current low-dose oral contraceptives is not explained by diagnostic suspicion and referral bias. Arch Intern Med. 1999;159:65–70.

    Article  PubMed  CAS  Google Scholar 

  22. Jick H, Jick S, Gurewich V, Myers M, Vasilakis C. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components. Lancet. 1995;346:1589–93.

    Article  PubMed  CAS  Google Scholar 

  23. Farmer R, Lawrenson R, Thompson C, Kennedy J, Hambleton I. Population-based study of risk of venous thromboembolism associated with various oral contraceptives. Lancet. 1997;349:83–8.

    Article  PubMed  CAS  Google Scholar 

  24. Lewis M, Heinemann LA, MacRae K, Bruppacher R, Spitzer W, with the Transnational Research Group on Oral Contraceptives and the Health of Young Women. The increased risk of venous thromboembolism and the use of third generation progestagens: role of bias in observational research. Contraception. 1996;54:5–13.

    Article  PubMed  CAS  Google Scholar 

  25. Lauritzen C. Comments on Desogestrel and Gestodene (third generation progestogens) and the incidence of thromboembolism. Horm Metab Res. 1996;28:225–47.

    Google Scholar 

  26. Jick H, Jick SS, Myers MW, Vasilakis C. Third-generation oral contraceptives and venous thrombosis. Lancet. 1997;349:731–2.

    Article  PubMed  CAS  Google Scholar 

  27. Poulter NR, Change CL, Marmot M, Farley TMM, Meirik O. Third-generation oral contraceptives and venous thrombosis. Lancet. 1997;349:732.

    Article  PubMed  CAS  Google Scholar 

  28. Lidegaard O. The influence of thrombotic risk factors when oral contraceptives are prescribed. Acta Obstet Gynecol Scand. 1997;76:252–60.

    PubMed  CAS  Google Scholar 

  29. Jamin C, de Mouzon J. Selective prescribing of third generation oral contraceptives. Contraception. 1996;54:55–6.

    Article  PubMed  CAS  Google Scholar 

  30. Dahlback, B. Inherited thrombophilia: resistance to activated protein C as a pathogenic factor of venous thromboembolism. Blood. 1995;85:607–14.

    PubMed  CAS  Google Scholar 

  31. Vandenbrouke JP, Koster T, Briet E, Reitsma PH, Brtina RM, Rosendaal FR. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet. 1994;344:1453–7.

    Article  Google Scholar 

  32. Helmerhorst F, Bloemenkamp K, Rosendaal F, Vandenbrouke J. Oral contraceptives and thrombotic disease: risk of venous thromboembolism. Thromb Haemost. 1997;78:327–33.

    PubMed  CAS  Google Scholar 

  33. Farley TM, Meirik O, Poulter NR, Chang CL, Marmot MG. Oral contraceptives and thrombotic diseases: impact of new epidemiological studies. Contraception. 1996;54:193–5.

    Article  PubMed  CAS  Google Scholar 

  34. Rosing J, Tans G, Nicolaes GAF, et al. Oral contraceptives and venous thrombosis: different sensitivities to activated protein C in women using second- and third-generation oral contraceptives. Br J Haematol. 1997;97:233–8.

    Article  PubMed  CAS  Google Scholar 

  35. Darney PD. OC practice guidelines: minimizing side effects. Int J Fertil. 1997;42(suppl 1):158–69.

    Google Scholar 

  36. Lindstedt G, Lundberg PA, Lapidis L, et al. Low sex-hormonebinding globulin concentration as an independent risk factor for the development of non-insulin dependent diabetes: twelve-year follow up of population study of women in Gothenburg. Sweden. Diabetes. 1991;40:123–8.

    CAS  Google Scholar 

  37. Rosa JC. The varying effects of progestins on lipid levels and cardiovascular disease. Am J Obstet Gynecol. 1988;158:1621–9.

    PubMed  Google Scholar 

  38. Kakis G, Powell M, Marshall A, et al. A two-year clinical study of the effects of two triphasic oral contraceptives on plasma lipids. Int J Fertil Menopausal Stud. 1994;39:283–91.

    PubMed  CAS  Google Scholar 

  39. Krauss RM, Burkman RT. The metabolic impact of oral contraceptives. Am J Obstet Gynecol. 1992;167:1177–84.

    PubMed  CAS  Google Scholar 

  40. Greenlund KJ, Webber LS, Srinivasan S, et al. Associations of oral contraceptive use with serum lipids and lipoproteins in young women: the Bogalusa heart study. Ann Epidemiol. 1997;7:561–7.

    Article  PubMed  CAS  Google Scholar 

  41. Notelovitz M, Feldman EB, Gillespy M, Gudat J. Lipid and lipoprotein changes in women taking low-dose, triphasic oral contraceptives: a controlled, comparative, 12-month clinical trial. Am J Obstet Gynecol. 1989;160:1269–80.

    PubMed  CAS  Google Scholar 

  42. London RS, Chapdelaine A, Upmalis D, Olson W, Smith J. Comparative contraceptive efficacy and mechanism of action of the norgestimate-containing triphasic oral contraceptive. Acta Obstet Gynecol Scand. 1992;71:9–14.

    Article  Google Scholar 

  43. Becker H. Supportive European data on a new oral contraceptive containing norgestimate. Acta Obstet Gynecol Scand. 1990;152(suppl):33–9.

    CAS  Google Scholar 

  44. Mann JI, Inman WH. Oral contraceptives and death from myocardial infarction. BMJ. 1975;2:245–8.

    PubMed  CAS  Google Scholar 

  45. Mann JI, Inman WH, Thorogood M. Oral contraceptive use in older women and fatal myocardial infarction. BMJ. 1976;2:445–7.

    PubMed  CAS  Google Scholar 

  46. Rosenberg L, Hennekens CH, Rosner B. Oral contraceptive use in relation to nonfatal myocardial infarction. Am J Epidemiol. 1980;111:59–66.

    PubMed  CAS  Google Scholar 

  47. Shapiro S, Slone D, Rosenberg L, et al. Oral-contraceptive use in relation to myocardial infarction. Lancet. 1979;1:743–7.

    Article  PubMed  CAS  Google Scholar 

  48. Ory HW. Association between oral contraceptives and myocardial infarction. JAMA. 1977;237:2619–22.

    Article  PubMed  CAS  Google Scholar 

  49. Slone D, Shapiro S, Kaufman D, et al. Risk of myocardial infarction in relation to current and discontinued use of oral contraceptives. N Engl J Med. 1981;305:420–4.

    Article  PubMed  CAS  Google Scholar 

  50. Croft P, Hannaford PC. Risk factors for acute myocardial infarction in women: evidence from the Royal College of General Practitioners’ oral contraception study. BMJ. 1989;298:165–8.

    Article  PubMed  CAS  Google Scholar 

  51. Rosenberg L, Kaufman DW, Helmrich SP. Myocardial infarction and cigarette smoking in women younger than 50 years of age. JAMA. 1985;253:2965–9.

    Article  PubMed  CAS  Google Scholar 

  52. Rosenberg L, Palmer JR, Lesko SM, Shapiro S. Oral contraceptive use and the risk of myocardial infarction. Am J Epidemiol. 1990;131:1009–16.

    PubMed  CAS  Google Scholar 

  53. Thorogood M, Mann J, Murphy M, Vessey M. Is oral contraceptive use still associated with an increased risk of fatal myocardial infarction? Report of a case-control study. Br J Obstet Gynaecol. 1991;98:1245–53.

    PubMed  CAS  Google Scholar 

  54. Sidney S, Petitti DB, Quesenberry CP, Klatsky AR, Ziel HK, Wolf S. Myocardial infarction in users of low-dose oral contraceptives. Obstet Gynaecol. 1996;88:939–44.

    Article  CAS  Google Scholar 

  55. Sidney S, Siscovick DS, Petitti DB, et al. Myocardial infarction and use of low-dose oral contraceptives: a pooled analysis of 2 US studies. Circulation. 1998;98:1058–63.

    PubMed  CAS  Google Scholar 

  56. WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone contraception. Acute myocardial infarction and combined oral contraceptives. Results of and international multicentre case-control study. Lancet. 1997;349:1202–9.

    Article  Google Scholar 

  57. Jick H, Jick S, Myers M, Vasilakis C. Risk of acute myocardial infarction and low-dose combined oral contraceptives. Lancet. 1996;347:627–8.

    Article  PubMed  CAS  Google Scholar 

  58. WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Ishaemic stroke and combined oral contraceptives. Results of an international, multicentre, case-control study. Lancet. 1996;348:498–505.

    Article  Google Scholar 

  59. Heinemann LA, Lewis MA, Thorogood M, et al., and the Transnational Research Group on Oral Contraceptives and the Health of Young Women. Case-control study of oral contraceptives and risk of thromboembolic stroke: results from international study on oral contraceptives and health of young women. BMJ. 1997;315:1502–4.

    PubMed  CAS  Google Scholar 

  60. WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Hemorrhagic stroke, overall stroke risk, and combined oral contraceptives. Results of an international, multicentre, case-control study. Lancet. 1996;348:505–10.

    Article  Google Scholar 

  61. Heinemann LA, Lewis MA, Thorogood M, et al., and the Transnational Research Group on Oral Contraceptives and the Health of Young Women. Thromboembolic stroke in young women: a European case-control study on oral contraceptives. Contraception. 1998;57:29–37.

    Article  PubMed  CAS  Google Scholar 

  62. Lewis MA, Sitzer WO, Heinemann LA, MacRae KD, Bruppacher R. Lowered risk of dying of heart attack with third generation pill may offset risk of dying of thromboembolism. BMJ. 1997;315:679–80.

    CAS  Google Scholar 

  63. Schwing PJ, Shelton J. Modeled estimates of myocardial infarction and venous thromboembolic disease in users of second and third generation oral contraceptives. Contraception. 1997;55:125–9.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. the Department of Internal Medicine, Portland Veterans Affairs Medical Center, Portland, Ore

    Erin S. LeBlanc MD

  2. the Department of Internal Medicine, Stanford University, Palo Alto, Calif

    Ami Laws MD

Authors
  1. Erin S. LeBlanc MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ami Laws MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

LeBlanc, E.S., Laws, A. Benefits and risks of third-generation oral contraceptives. J GEN INTERN MED 14, 625–632 (1999). https://doi.org/10.1046/j.1525-1497.1999.08108.x

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1046/j.1525-1497.1999.08108.x

Key words

Search

Navigation